Coeptis Therapeutics Holdings Inc (NASDAQ:COEP) has a beta value of -0.83 and has seen 14.42 million shares traded in the recent trading session. The company, currently valued at $10.81M, closed the recent trade at $0.29 per share which meant it lost -$0.05 on the day or -13.56% during that session. The COEP stock price is -655.17% off its 52-week high price of $2.19 and 0.0% above the 52-week low of $0.29. The 3-month trading volume is 244.73K shares.
Coeptis Therapeutics Holdings Inc (NASDAQ:COEP) trade information
Sporting -13.56% in the red today, the stock has traded in the red over the last five days, when the COEP stock price touched $0.29 or saw a rise of 23.68%. Year-to-date, Coeptis Therapeutics Holdings Inc shares have moved -62.84%, while the 5-day performance has seen it change -17.94%. Over the past 30 days, the shares of Coeptis Therapeutics Holdings Inc (NASDAQ:COEP) have changed -13.04%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Coeptis Therapeutics Holdings Inc (COEP) estimates and forecasts
Figures show that Coeptis Therapeutics Holdings Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -74.89% over the past 6 months, with this year growth rate of 13.48%, compared to 15.20% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -311.69% over the past 5 years.
COEP Dividends
Coeptis Therapeutics Holdings Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
